Blisibimod: Phase III ongoing

Anthera said an independent DSMB recommended continuation of the double-blind, placebo-controlled, international Phase III CHABLIS-SC1 trial of blisibimod based on an interim futility analysis of the SRI-6 response at 24 weeks. CHABLIS-SC1 is evaluating once-weekly subcutaneous blisibimod for 52 weeks in about 400 patients with active SLE who have not achieved optimal resolution with corticosteroid use. Patients will have the option to enroll in an open-label, follow-up safety study. ...